By Jonathan D. Rockoff 

Two members of Congress investigating drug-price increases asked Valeant Pharmaceuticals International Inc. on Friday for information that would help explain why it raised the prices earlier this year for two commonly-used heart drugs.

Valeant was sent a letter from Sen. Bernie Sanders (I., Vt.) and Rep. Elijah Cummings (D., Md.) seeking information such as the cost of ingredients and of manufacturing blood-pressure drug Nitropress and heart-rhythm treatment Isuprel "in order to evaluate the underlying causes" of their price increases earlier this year.

In the letter, the lawmakers also asked the Canadian company to explain the factors involved in the price increases, expected profits and the names of those involved in the decision.

On the day in February it bought the rights to the drugs, Valeant raised the list price of a vial of Isuprel more than sixfold to $1,346.62 and more than tripled Nitropress to $805.61.

The increases were featured in a Wall Street Journal article in April, cited in the congressional letter to Valeant, about how some drug companies are using deal-making to acquire rights to certain drugs and then increasing the prices. Hospitals, which buy the drugs for use during heart procedures or emergency treatment, complain the increases are hurting their budgets.

Since October, Sen. Sanders, who is seeking the Democratic nomination for president, and Rep. Cummings have been sending letters to pharmaceutical companies and generally investigating significant price increases for certain drugs in an effort to understand the reasons.

Sen. Sanders and Rep. Cummings also sent a letter on Friday to Hospira Inc., which they said makes Isuprel and Nitropress for Valeant, seeking documents and information about the costs of making the two medicines, any "material changes" to the manufacturing and the contracts with Valeant.

Valeant and Hospira didn't immediately respond to requests for comment.

Write to Jonathan D. Rockoff at Jonathan.Rockoff@wsj.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Valeant Pharma (NYSE:VRX)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Valeant Pharma Charts.
Valeant Pharma (NYSE:VRX)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Valeant Pharma Charts.